Meta-Analysis
Copyright ©The Author(s) 2020.
World J Gastrointest Oncol. Nov 15, 2020; 12(11): 1346-1363
Published online Nov 15, 2020. doi: 10.4251/wjgo.v12.i11.1346
Table 1 Characteristics of included studies
Ref.
Trial
Clinical trials. gov, No.
Study design
Phase
Case, experimental vs control, (n)
Intervention methods
ORR (%)
DCR (%)
12-mo OS (%)
12-mo PFS (%)
Bang et al[28] 2018JAVELIN Gastric 300NCT02625623RCTIII371, 185 vs 186Avelumab 10 mg/kg Q2 W vs paclitaxel 80 mg/m2 or irinotecan 150 mg/m2 1, 8, 15 d of 4-wk cycles.2.222.2NANA
Bang et al[29] 2019KEYNOTE-059 (cohorts 2 and 3)NCT02335411Single-armII31Pembrolizumab 200 mg on day 1 of 21-d cycles.25.835.563.0NA
Boku et al[30] 2019ATTRACTION-4NCT02746796RCTII40, 21 vs 19Nivolumab 360 mg Q3 W + SOX or Cape OX.65.884.2NANA
Chen et al[31] 2020ATTRACTION-2NCT02267343RCTIII493, 330 vs 163Nivolumab 3 mg/kg Q2 W vs placebo 3 mg/kg Q2 W.11.940.387.19.3
Chung et al[32] 2019JAVELIN Solid TumorNCT01772004Dose-escalationI150Avelumab 10 mg/kg Q2 W.6.745.338.012.6
Doi T et al[33] 2019JAVELIN Solid Tumor JPN trialNCT01943461Single-armI40Avelumab 10 mg/kg Q2 W10.052.531.0NA
Fuchs et al[34] 2018KEYNOTE-059 (cohorts 1)NCT02335411Single-armII259Pembrolizumab 200 mg Q3 W.11.627.023.4NA
Herbst et al[35] 2019JVDFNCT02443324Single-armIa/b41Pembrolizumab 200 mg on day 1 + ramucirumab 10 mg/kg days 1-8.7.351.230.812.3
Janjigian et al[36] 2018CheckMate-032NCT01928394Dose-escalationI/II59Nivolumab 3 mg/kg Q2 W.12.032.039.08.0
Kelly et al[37] 2020NANCT02340975RCTIb/II 27 Durvalumab 20 mg/kg + tremelimumab 1 mg/kg Q4W.7.4NA37.0NA
Muro et al[38] 2016KEYNOTE-012NCT01848834Single-armIb39Pembrolizumab 10 mg/ kg Q2 W.22.033.042.0NA
Shah et al[39] 2019KEYNOTE-180NCT02559687Single-armII121Pembrolizumab 200 mg Q3 W.9.930.628.0NA
Shitara et al[40] 2018KEYNOTE-061NCT02370498RCTIII592, 296 vs 296Pembrolizumab 200 mg Q3 W vs paclitaxel 80 mg/m2 1, 8, 15 d of 4-wk cycles11.120.740.0NA